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Abstract
Background: Understanding blood-brain barrier responses to inflammatory stimulation (such as lipopolysaccharide
mimicking a systemic infection or a cytokine cocktail that could be the result of local or systemic inflammation) is
essential to understanding the effect of inflammatory stimulation on the brain. It is through the filter of the blood-
brain barrier that the brain responds to outside influences, and the blood-brain barrier is a critical point of failure in
neuroinflammation. It is important to note that this interaction is not a static response, but one that evolves over
time. While current models have provided invaluable information regarding the interaction between cytokine
stimulation, the blood-brain barrier, and the brain, these approaches—whether in vivo or in vitro—have often been
only snapshots of this complex web of interactions.
Methods: We utilize new advances in microfluidics, organs-on-chips, and metabolomics to examine the complex
relationship of inflammation and its effects on blood-brain barrier function ex vivo and the metabolic
consequences of these responses and repair mechanisms. In this study, we pair a novel dual-chamber, organ-on-
chip microfluidic device, the NeuroVascular Unit, with small-volume cytokine detection and mass spectrometry
analysis to investigate how the blood-brain barrier responds to two different but overlapping drivers of
neuroinflammation, lipopolysaccharide and a cytokine cocktail of IL-1β, TNF-α, and MCP1,2.
Results: In this study, we show that (1) during initial exposure to lipopolysaccharide, the blood-brain barrier is
compromised as expected, with increased diffusion and reduced presence of tight junctions, but that over time,
the barrier is capable of at least partial recovery; (2) a cytokine cocktail also contributes to a loss of barrier function;
(3) from this time-dependent cytokine activation, metabolic signature profiles can be obtained for both the brain
and vascular sides of the blood-brain barrier model; and (4) collectively, we can use metabolite analysis to identify
critical pathways in inflammatory response.
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Conclusions: Taken together, these findings present new data that allow us to study the initial effects of
inflammatory stimulation on blood-brain barrier disruption, cytokine activation, and metabolic pathway changes
that drive the response and recovery of the barrier during continued inflammatory exposure.
Keywords: Lipopolysaccharide, Cytokine, Tight junctions, IL-1β, TNF-α, MCP1,2, Brain-on-chip, Micro-organ, Mass
spectrometry, Metabolomics
Background
Recent research has shown that systemic infection and
inflammation not only affect multiple organs in the body
but also the central nervous system (CNS). An excellent
example of this is maternal immune activation, which
increases the risk of neurological disorders in the gestat-
ing fetus [1–7]. Previous studies have determined that
traumatic brain injuries and cancer can activate the im-
mune system and affect the CNS [8, 9]. These reports
support the idea that substances created by peripheral
immune responses are crossing the blood-brain barrier
(BBB) and affecting CNS function. Furthermore, im-
mune activators such as lipopolysaccharide (LPS) have
been shown to impair intestinal barrier function, and in
neural tissue culture, LPS has been reported to induce
cytokine activation and cell damage [10–12]. Recent ani-
mal studies have illustrated that LPS exposure in preg-
nant mice elevates fetal IL-6 and perturbs fetal brain
development [7, 13]. Other data collected in rodents
suggest that the BBB is relatively impermeable to LPS
[14]. While the rodent work is compelling, it can be dif-
ficult to reconcile with human postmortem studies [15,
16] and observations made in cell culture, which seem
to indicate a much more pronounced effect of LPS on
the BBB [17]. One limitation of these studies is that due
to the high cost of sample collection from both animals
and human patients, often only a single time point after
a single, short-duration exposure is analyzed. Systemic
immune activation is a process that develops over time
[18, 19], and thus, BBB function should be assessed in a
dose- and time-dependent manner. In addition to LPS
directly crossing the human BBB, the cytokines it in-
duces in the vasculature that comprise the BBB certainly
can cross the barrier and affect its function [20–22].
To aid our further understanding of how the BBB re-
sponds to immune activation, we have developed a novel
dual-chamber microfluidic device that models BBB func-
tion. It utilizes human primary cells and enables flow
and sample collection from both compartments (brain
and vascular side) separated by a barrier [23]. By using
this novel technology, we are able to continually perfuse
the vascular side of the BBB model with LPS or a cyto-
kine cocktail and to collect effluent samples from before
and during the course of exposure. In these studies, our
data suggest that LPS has a time-dependent effect on
BBB permeability, cytokine activation, and metabolic ac-
tivity, and we observe a robust metabolic pathway acti-
vation response using a mixture of TNF-α, IL-1β, and
MCP1,2.
Methods
NeuroVascular Unit microfluidic device
The NeuroVascular Unit (NVU) was fabricated by the
Vanderbilt Institute for Integrative Biosystems Research
and Education (VIIBRE) Microfabrication Core. The
basic design is a two-chamber system wherein the cham-
bers are constructed of polydimethylsiloxane (PDMS)
and divided by a porous 0.2-μm polycarbonate mem-
brane (Sigma-Aldrich, St. Louis, MO, USA). Each cham-
ber has its own inlet and outlet for perfusion. The
device can be perfused in any orientation, so that cells
seeded into a chamber can be induced by gravity to ad-
here to one side of the porous membrane and by invert-
ing the device and seeding the opposite side with a
different cell type, they can be grown in opposition to
one another to form the BBB [23]. As previously de-
scribed [23], the bottom/vascular chamber is 2.9 μL in
volume, with uniform shear forces across the chamber,
while the top/brain chamber is 18 μL in volume. The
top perfusion layer is attached to the brain chamber and
allows a mild media exchange without the introduction
of shear stress onto the neurons and co-differentiating
astrocytes (cultured within the collagen) and the astro-
cytes and pericytes that are adhered to the barrier.
Cell culture
Cell culture was carried out as previously described [23].
In brief, cells used to establish our NVU BBB model in-
clude primary human brain-derived microvascular endo-
thelial cells (hBMVEC) from Applied Cell Biology
(Kirkland, WA, USA) and pericytes and astrocytes from
ScienCell (Carlsbad, CA, USA) and ATCC (Manassas, VA,
USA), respectively. Before endothelial cells were intro-
duced into the lower vascular chamber of the NVU, the
device was coated with laminin at 9.6 μg/mL for 24 h at
37°C. On day 0, hBMVECs were loaded into the vascular
chamber (1 × 106 cells/mL), followed by device inversion to
allow cell attachment to the membrane. At day 1, media
was perfused at 2 μl/min, and the hBMVECs were allowed
to grow for 12 days to reach confluence and establish tight
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junctions. On day 12, the device was returned to its ori-
ginal orientation and a 2:1 mix of primary human astro-
cytes and pericytes was loaded into the upper brain
chamber and allowed 1–2 days to reach confluence. On
day 14, collagen gel containing 4 million human induced
pluripotent stem cell (hiPSC)-derived human cortical neu-
rons and co-differentiating astrocytes per milliliter was
loaded on top of the astrocytes and pericytes. The hiPSC-
derived neurons and co-differentiating astrocytes were dif-
ferentiated to days 95–200 via dual-SMAD inhibition
followed by terminal differentiation by adapting methods
described elsewhere, except that LDN was used at 4 μM
[24–27]. The collagen gel was given 2 h to solidify before
restarting perfusion of the brain chamber. For the first
3 days after the neurons were added, the brain chamber
was perfused with media containing Rho-associated coiled-
coil kinase (ROCK) inhibitor (10 μM, Tocris) Y-27632
(Sigma-Aldrich, St. Louis, MO, USA) to help the neurons
survive the stress of replating [28–31]. Once the ROCK in-
hibitor was no longer needed, we used media without it,
and the NVU was ready for testing.
LPS and cytokine cocktail exposure and sample collection
LPS was purchased from Sigma-Aldrich (St. Louis, MO,
USA) and applied to the vascular chamber at 100 μg/mL,
which is a concentration that has previously been shown
to disrupt tight junctions and increase intestinal perme-
ability [32]. Effluent samples were collected from both the
vascular and brain chambers of the NVU at three time
points: before exposure (denoted as 0), 6 h after exposure,
and 24 h after exposure. For the cytokine cocktail, 100 ng/
ml of TNF-α, IL-1β, and MCP1,2 (Sigma-Aldrich, St.
Louis, MO, USA) were diluted in vascular media [23] and
applied to the vascular chamber only for 24 h.
Live/dead evaluation
To evaluate the DNA integrity of the cells, a live/dead
assay kit (Cat. No. L3224, Fisher, Waltham, MA, USA)
was used according to the manufacturer’s instructions
using 1 μM of calcein AM (i.e., live stain indicator) and
2 μM of ethidium homodimer-1 (i.e., dead stain indica-
tor), as previously described [33]. Cells that are stained
with red are considered unhealthy. All live/dead images
were taken from the same frame with different excitation
wavelengths.
FITC-dextran diffusion and transendothelial electrical
resistance
Fluorescein isothiocyanate-dextran (FITC-dextran) of
10 kDa (Sigma-Aldrich, St. Louis, MO, USA) was pre-
pared at 1 μg/mL (100 nM) in cell culture media for dif-
fusion testing. As previously described [23], the vascular
compartment of the NVU was perfused with 10 kDa so-
lution for 23 h. In our original protocol [23] at 23 h, the
flow on both sides (vascular and brain chambers) was
stopped for 1 h, allowing the dextran to diffuse across
the BBB and accumulate in the brain compartment.
After 1 h, perfusion of both chambers was restarted and
individual effluents were collected for fluorescent inten-
sity analysis using a plate reader (TECAN M1000). We
have shown that the stop-flow was not necessary and
now collect fluid for 1 h of continuous perfusion with
FITC-dextran. By measuring FITC-dextran diffusion
across the membrane, we were able to evaluate the ef-
fectiveness of the BBB [34].
Transendothelial electrical resistance (TEER) measure-
ments were performed using our custom-built multi-
frequency impedance analyzer based on an AD5933 chip
(Analog Devices, Nashua, NH, USA) utilizing a four-
probe approach [35]. The largest changes in impedance
as a function of BBB maturation were observed at
15 kHz, and all TEER measurements used in this study
to evaluate the effect of LPS on BBB function are re-
ported at that frequency.
Tight junction staining
Fluorescent labeling of the tight junctions was evaluated
using a Zeiss Axiovert 200 automated microscope
equipped with a CoolSnap CCD camera. Collected im-
ages were analyzed with ImageJ. Tight junction staining
was conducted as detailed in [36], using ZO-1 and
claudin-5 (Invitrogen, Grand Island, NY, USA) directly
conjugated to Alexa 488 [37]. Briefly, greyscale measure-
ments of the border between cell plasma membranes
were taken for ten different cell-to-cell junctions in four
different plates, and an average intensity was derived for
each culture condition [23].
Cytokine ELISA
Effluent samples taken before 6 h and after 24 h of LPS
exposure were collected and diluted 1:3 for cytokine
analysis using either the V-Plex Human Cytokine Kit
(Meso Scale Discovery, Rockville, MD, USA) or Quanti-
kine enzyme-linked immunosorbent assay (ELISA) for
TNF-α and IL-1β (R&D Systems, Inc., Minneapolis, MN,
USA). Sample preparation was carried out as described
previously [38].
Data analysis
The statistical analysis of the mass spectrometry data is
described within the section on metabolite data processing
and analysis. All other data were analyzed in a blinded
fashion using GraphPad software. Analysis of variance
(ANOVA) models were used to analyze the data and con-
tained one between-subjects variable, such as “treatment”
and “trial number” (e.g., before and after drug treatment).
The appropriateness of ANOVA models was evaluated by
considering the distributional properties of the variables
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studied and by the adequacy of the homogeneity of vari-
ance assumption. The Greenhouse-Geisser (or Huynh-
Feldt) adjustment was used for all within-subjects effects
containing more than two levels in order to protect
against violations of the sphericity/compound symmetry
assumptions when a repeated measure ANOVA was used.
Metabolite extraction
All solvents used for metabolite extraction (methanol,
water, acetonitrile, and formic acid) were liquid chro-
matography (LC)-mass spectrometry (MS) grade
(Fisher Scientific, Fair Lawn, NJ, USA). Metabolites
were extracted from NVU media using a MeOH:H2O
(80:20, v:v) solvent extraction mixture. A volume of
500 μL of cold (−20°C) extraction mixture was added
to each 60 μL aliquot of media, vortexed for 30 s, and
incubated at −80°C overnight to precipitate proteins.
After incubation, samples were cleared by centrifuga-
tion at 15,000 rpm for 15 min, and the resulting super-
natant was removed and evaporated to dryness in a
vacuum concentrator. Dried extracts were reconsti-
tuted in 60 μL of C18 reconstitution solvent mixture
containing 98:2 (v:v) H2O:ACN with 0.1% formic acid
for reverse phase analysis, followed by centrifugation
for 5 min at 15,000 rpm to remove insoluble debris.
Quality control samples were prepared by combining
equal volumes (10 μL) of each sample type (experi-
mental design and sample workflow are shown in
Additional file 1).
Mass spectrometry
Ultraperformance liquid chromatography-ion mobility-
mass spectrometry (UPLC-IM-MS) and data-independent
MS acquisition with simultaneous analysis of molecular
fragmentation (MSE) were performed on a Waters Synapt
G2 HDMS (Milford, MA, USA) mass spectrometer
equipped with a Waters nanoAcquity UPLC system and
autosampler (Milford, MA, USA), as previously described
[39]. Metabolites were separated on a reverse phase
1 mm× 100 mm HSS T3 C18 column packed with 1.8-μm
particles (Waters, Milford, MA, USA) held at 45°C. Liquid
chromatography was performed using a 30-min gradient
at a flow rate of 75 μL min−1 using mobile phase A (0.1%
formic acid in H2O) and mobile phase B (0.1% formic acid
in ACN). The following elution gradient was used for ana-
lysis: 0 min, 99% A; 1 min, 99% A; 10 min, 40% A; 20 min,
1% A; 22 min, 1% A; 25 min, 99% A.
High-definition MSE (HDMSE) analyses were run using
resolution mode, with a capillary voltage of 2.75 kV, source
temperature at 100°C, sample cone voltage at 30 V, extrac-
tion cone voltage at 5 V, source gas flow of 400 mL min−1,
desolvation gas temperature of 325°C, He cell flow of
180 mL min−1, and an ion mobility (IM) gas flow of
90 mL min−1. The data were acquired in positive ion mode
from 50 to 2000 Da with a 1-s scan time; leucine
enkephalin was used as the lock mass (m/z 556.2771). All
analytes were analyzed using MSE with an energy ramp
from 10 to 40 eV and an injection volume of 5 μL [40]. (For
the work flow, see Additional file 1.)
Metabolite data processing and analysis
The acquired UPLC-IM-MSE data were imported, proc-
essed, normalized, and interpreted in Progenesis QI v.2.1
(Nonlinear Dynamics, Newcastle, UK). Each UPLC-IM-
MSE data file was imported as an ion intensity map (used
for visualization in both m/z and retention time dimen-
sions), followed by retention time alignment and peak
picking. Peak picking was performed on individual aligned
runs by matching peaks in an aggregate data set that was
created from all aligned runs. Following peak picking, the
features (retention time and m/z pairs) were reduced
using both adduct ([M +H]+, [M+Na]+, [M+ K]+, etc.)
and isotope deconvolution. Data were normalized to all
compounds as an abundance ratio between the run being
normalized and a reference run. Statistically significant
changes were identified using multivariate statistical ana-
lysis, including principal component analysis (PCA), and p
values were generated using ANOVA or pairwise com-
parison. Volcano plots (log2 fold change vs. −log10 p value)
were generated for basal conditions (no LPS treatment)
vs. 100 μg/mL LPS stimulation after either 6 or 24 h. Four
biological replicates (NVU) and two technical replicates
from each sample type were used to calculate the fold
change and p value, and features were considered differen-
tially expressed only if they met both criteria of fold
change ≥|2| and significance (p ≤ 0.05); we have termed
this list “prioritized metabolites”. Feature lists generated
from different individual comparisons were visually com-
pared using Venn diagrams generated by the Venny soft-
ware package [41]. Statistically significant metabolites or
compounds were assigned tentative structural identifica-
tions using accurate mass measurements (<10 ppm error)
and isotope distribution by searching the Human Metabo-
lome Database (HMDB) [40], METLIN [42], MassBank
[43], and the NIST 14 Tandem Database and Search Pro-
gram of the National Institute of Standards and Technol-
ogy [44]. Following tentative structural identifications,
further data processing was performed by removing me-
tabolites associated with drugs, plants, food, and microbial
origin. Metabolite peak identifications were putatively
assigned using product ions observed in the fragment ion
spectra analyzed in HDMSE mode by searching the afore-
mentioned databases. Ion mobility separations were used
to isolate precursor ions and correlate product ions [45].
Metabolic activity network mummichog analysis
Metabolomics pathway analysis was performed by
mummichog software 1.0.5 using default parameters.
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Compound ions measurement files exported from Pro-
genesis QI analysis software were used to generate the
mummichog input files. mummichog tested the enrich-
ment of input metabolites against random data
resampled from the list of compounds by permutations
and produced an empirical p value for known biological
pathways. Input metabolites in the significant pathways
(p value ≤0.05) were linked in a network figure by
known metabolic pathways [46].
Results
Inflammatory signals and cell viability
Although it has been well established that exposure to LPS
induces cytokine responses [16, 32], and in the case of other
organ systems that LPS exposure has been linked to re-
duced tight junction protein expression [17], relatively little
is known about its effects on the BBB and how this com-
pares to the direct cytokine exposure that LPS is supposed
to induce. To study the effects of inflammatory signals on
BBB function, we leveraged novel microfluidic technology
in a dual-chambered device, creating a system that contains
the relevant cell types for BBB formation and enables these
cells to form the barrier in the presence of flow and a differ-
ential serum concentration from the vascular to the brain
side of the device [23]. Once the brain-derived endothelial
cells, astrocytes, and pericytes have had a chance to form
the basis for the BBB, hiPSC-derived cortical neurons and
co-differentiating astrocytes are suspended in a collagen gel
and loaded on top of the astrocytes and pericytes. This en-
tire component is what we call the NeuroVascular Unit
(NVU), which previously has been shown to restrict diffu-
sion of small molecules and facilitate active transport [23].
Having established our cellular model of the BBB (Fig. 1a),
we then sought a concentration of LPS and cytokine cock-
tail that, while activating the system, would not cause cell
death. We wanted the highest concentration that did not
increase cell death from control. Over the dose ranges
tested (25 to 100 μg/ml), we found that 100 μg/mL showed
no cell death in either the vascular chamber containing
endothelial cells (Fig. 1b) or in the brain chamber contain-
ing pericytes, astrocytes, and neurons (Fig. 1c), as assessed
by live/dead staining after 24 h of LPS or cocktail exposure.
Blood-brain barrier transport of inflammatory signals
The custom microfluidic device used to generate the
organ-on-chip model of the BBB and the NVU consists
Fig. 1 NeuroVascular Unit (NVU) layout and live/dead staining
before and after inflammatory stimulation. a Artistic rendering of the
NVU and the cells contained within. b Vascular chamber live/dead
and c brain chamber with and without 24-h exposure to 100 μg/mL
LPS or cytokine cocktail of 100 ng/ml TNF-α, IL-1β, and MCP1,2.
Green and red channels are taken from the same frame. Scale bar
is 200 μm
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primarily of PDMS, a polymer with many desirable fea-
tures for cell culture, being easily molded, cell-compatible,
and gas-permeable, to name a few. We note, however, that
it also has been shown in tests to absorb small hydropho-
bic molecules [47–49]. To know the actual dose of inflam-
matory signals reaching our NVU BBB, we first looked at
absorption in an empty device (Fig. 2a), and from these
findings, we observed that while we started with relatively
high concentrations, final exposure was much closer to
physiologic ranges seen in patients at the onset of severe
sepsis (~300 pg/ml) [50], with the greatest loss being LPS
itself. When we next examined the transport of LPS vs.
cocktail across the BBB in the NVU, we saw that the per-
centage of LPS transport was 46% (Fig. 2b) and that of
TNF-α and IL-1β was 31 and 35%, respectively (Fig. 2c,d).
These data indicate that both LPS and cytokines it often
stimulates cross the barrier with relatively high efficacy.
Inflammatory stimulation effects on blood-brain barrier
integrity
To measure directly how BBB permeability was changing































Fig. 2 Blood-brain barrier transport of inflammatory signals. a Concentration in pg/ml in effluent going into an empty bioreactor and effluent
coming out after 24 h of continuous perfusion at 2 μl/min. b Concentration of LPS in vascular and brain chambers over time. At 24 h, the brain is
significantly lower than vascular (p = .0035, N = 8). c ELISA of TNF-α in NVU before and after treatment of the vascular side only with cytokine
cocktail containing 100 ng/ml TNF-α, IL-1β, and MCP1,2 shows 31% transport of TNF-α to neuronal/brain chamber. d ELISA of IL-1β in NVU before
and after treatment of the vascular side only with cytokine cocktail containing 100 ng/ml TNF-α, IL-1β, and MCP1,2 shows 36% transport of IL-1β
to neuronal/brain chamber (N = 8)
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diffusion of 10-kDa FITC-dextran across the NVU BBB.
As was expected, at time 0, before LPS exposure, diffu-
sion was extremely low; however, after 6 h of exposure
to LPS introduced on the vascular side, diffusion was
significantly increased four times over the control at
time 0 (p = .0001, N = 7). Interestingly, at 24 h, diffusion
was reduced from its level at 6 h but had not returned
to pre-exposure levels (Fig. 3a). Having thus established
a time-course effect of LPS on membrane resistance and
barrier diffusion, we then assessed how this compared to
direct cytokine stimulation and found the effect on BBB
permeability to be similar (Fig. 3b). We also considered
how transendothelial resistance changed as a function of
LPS and time. During early exposures to LPS for six
continuous hours, TEER measurements suggest that the
permeability of the NVU BBB does increase as a func-
tion of time and dose, as observed by a reduction in
resistance. An inverse response is observed after 24 h of
exposure to LPS, however; i.e., TEER measurements
show an increase in membrane resistance as a function
of time and dose (Fig. 3c).
Additional experiments showed the expression and
localization of tight junction proteins as a response to
dose and time of LPS exposure. For both claudin-5 and
ZO-1, we saw a dose-dependent reduction in levels of ex-
pression at 6 h of LPS exposure and an increase after 24 h
(Fig. 3d, e). When the staining intensity was quantified
over multiple samples, we observed a significant decrease
in both tight junction proteins at 6 h (−12% ZO-1, −18%
Clad-5 (p ≤ .03, N = 10)) and a significant increase at 24 h
(31% ZO-1, Clad-5 22% (p ≤ .03, N = 10)) for all concen-
trations tested (Fig. 3f shows the quantitation of the stain-
ing). These results indicate that the changes in the NVU




























































BBB Permeability During Cytokine
Cocktail Exposure
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Fig. 3 FITC-dextran diffusion across the BBB and tight junction staining in response to inflammatory stimulation over time. a FITC-dextran diffu-
sion across the BBB is significantly increased at 6 h (p = .05, N = 7) and reduced from the 6-h point at 24 h (p = .05, N = 7). b FITC-dextran diffusion
across the BBB is significantly increased 24 h after start of cytokine cocktail exposure (p = .01, N = 4). c TEER of dose- and time-dependent effect
with LPS response. d Claudin-5 staining of tight junctions shows dose- and time-dependent response, with staining decreasing at early time
points with dose and increasing at later time points with dose. e ZO-1 staining of tight junctions shows dose- and time-dependent response, with
staining decreasing at early time points with dose and increasing at later time points with dose. f Mean grayscale intensity of the images such as
those in b and c for Claudin-5 and ZO-1 release in response to LPS concentration over time
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tight junction protein expression. Taken together, these
findings argue that although the BBB may initially become
more permeable when exposed to this foreign immuno-
gen, over time it begins to block LPS passage—this is re-
lated to tight junction protein expression. These results
also showed similar disruption of the BBB by cytokines, as
was seen with LPS, suggesting overlapping mechanisms.
Cytokine activation in BBB model as a result of LPS
stimulation
The link between LPS exposure and cytokine activation has
been well established in both cell culture and animal
models. Despite this wealth of data, few studies have inves-
tigated cytokine response as a function of time or changes
in barrier permeability. Using 50 μL of effluent collected
from the vascular and brain side of our NVU devices at 0,
6, and 24 h of LPS exposure, we ran ELISA detection for a
battery of cytokines (GM-CSF, IL12-p40, IL-15, IL-16, IL-
1a, IL-5, IL-17A, TNF-b, VEGF, TNF-α, IL-1β ). Interest-
ingly, of the 11 cytokines investigated, over half exhibited
significant changes in one or more of the chambers and
time points under investigation; however, different patterns
of cytokine release and membrane permeability were ob-
served when individual cytokines were studied alone. For
example, the cytokine granulocyte-macrophage colony-
stimulating factor (GM-CSF) known to be active in BBB
disruption [51] showed a pattern of release in both vascular
and brain chambers very similar to that seen in FITC-
dextran diffusion, wherein release was highest at 6 h and
markedly reduced at 24 h (Fig. 4a). However, if we look at a
cytokine such as IL-17A, which is known to stimulate neur-
ite outgrowth [52], its release levels in the vascular chamber
were significantly reduced at 6 and 24 h, but increased at
these time points in the brain chamber (Fig. 4b). Finally,
the canonical cytokine TNF-α, which is known to be part
of the inflammatory response to BBB disruption [53, 54],
showed an increase in release over time in both the vascu-
lar and brain chambers (Fig. 4c). (For a complete list of all
the cytokines and their fold changes, see Additional file 2.)
From these findings, we perceive a complex array of cyto-
kine changes that occur over time in the BBB, and these
changes may result in the observed alterations of barrier
permeability.
Metabolic response of BBB model to LPS and cytokine
cocktails
In addition to looking at the traditional response of our
BBB model to inflammatory stimulation in terms of cyto-
kine activation, we also used novel technology to gain a bet-
































































































































Fig. 4 ELISA quantification of cytokine response to LPS stimulation over time. a Vascular chamber and brain chamber both elevate GM-CSF at 6 h but
not 24 h (p = .02, p = .016, N = 7). b Vascular chamber decreases IL-17A at 6 and 24 h (p = .05, p = .05, N = 7), whereas brain chamber increases IL-17A at
6 and 24 h (p = .001, p = .002, N = 7). c Vascular chamber and brain chamber show similar time-dependent elevations in TNF-α (p = .01, p = .01, N = 7)
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to these challenges. To investigate the metabolic response
of our BBB to inflammatory stimulation over time, UPLC-
IM-MS was used to determine if the global molecular
metabolic profiles change throughout the course of LPS ex-
posure (see Additional file 1). Principal component analysis
plots of the UPLC-IM-MS/MS for LPS samples illustrate
distinct separations between the control and treated sample
types and between the 6- and the 24-h time points (Fig. 5a,
b). Volcano plots for the vascular chamber (Fig. 5c) (p ≤
0.05 and fold changes ≥│2│) illustrate that critical metab-
olites are released over time (6 h of LPS stimulation; see
colored points). We observe the same trend in the brain
chamber after 6 h of LPS stimulation (Fig. 5d). Moreover,
after 24 h of LPS stimulation, more metabolites that met
the significance criteria were released (Fig. 5c, d, right).
These global metabolic profile data indicate that metabolic
(Control vs. 6h LPS)
Vascular Chamber
(Control vs. 24h LPS)
Brain Chamber








Fig. 5 UPLC-IM-MS global metabolomic profile analysis upon LPS treatment. a Global principal component analysis (PCA) of LPS-treated (6 and 24 h)
and untreated sample types (brain chamber) illustrating that three distinct metabolic signatures or profiles were observed in the UPLC-IM-MS analysis.
b Trend analysis for m/z 191.1529 illustrates the ability to observe trends in normalized metabolite abundances indicative of treatment exposure times.
c Volcano plot comparing basal conditions (no LPS treatment) vs.100 μg/mL LPS stimulation in the vascular chamber. In these plots, we observed 64
(6 h) and 132 (24 h) unique compounds that met our significant criteria (fold change ≥│2│ and p≤ 0.05) in the vascular response to LPS. d Volcano
plot comparing basal conditions (0 LPS) vs.100 μg/mL LPS stimulation in the brain chamber. We observed 60 (6 h) and 90 (24 h) unique metabolites/
compounds that met our significant criteria (fold change ≥│2│ and p≤ 0.05) in the brain response to LPS
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changes occurred after 6 h and before 24 h of stimulation
(Fig. 5c, d) in both chambers.
In an IM-MS analysis of response to the cytokine
cocktail, we observe two distinct groups (0 h treat-
ment and 24 h treatment) using PCA (Fig. 6a). Vol-
cano plots for the vascular chamber (Fig. 6b) (p ≤ 0.05
and fold changes ≥│2│) illustrate that both time and
treatment have a significant effect on metabolic activ-
ity, with treatment causing the biggest impact. We see
the same trend in the brain chamber (Fig. 6c). Venn
diagrams of the global metabolite profiles show that
while a significant number of metabolites are observed
after 6 and 24 hours of LPS stimulation, greater than
50% of the compounds observed that met the signifi-
cance criteria are time-specific (Fig. 7a, b). We do note
more significant changes in the global metabolic pro-
files during the 24-h LPS stimulation when compared
to 6 h of stimulation. These observations may be at-
tributed to the cumulative effect of continuous LPS re-
sponse (Fig. 7c, d). These same trends were consistent
Fig 6 UPLC-IM-MS global metabolomic profile analysis upon cytokine cocktail treatment. a Global principal component analysis (PCA) of cytokine
cocktail-stimulated (0 and 24 h) sample types (brain chamber) illustrating that two distinct metabolic signatures or profiles were observed in the
UPLC-IM-MS analysis. b Volcano plot comparing basal conditions (no cytokine cocktail treatment) at 0 and 24 h as well as treated (100 ng/ml
cocktail) in the vascular chamber. c Volcano plot comparing basal conditions (no cytokine cocktail treatment) at 0 and 24 h as well as treated
(100 ng/ml cocktail) in the brain chamber
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with our observations following cytokine cocktail acti-
vation (Fig. 7e, f ), however, and the inflammatory
stimulation was likely a bit stronger given less absorp-
tion by the PDMS (Fig. 2a). We found many more me-
tabolites significantly affected by treatment (Fig. 7g,
h). The observed global metabolic response to LPS be-
tween the vascular and brain chambers (across the
BBB) after 6 h of LPS stimulation is similar (see Fig. 8a,
b). In contrast, the observed global metabolite profile
data for 24 h of LPS stimulation suggest that more sig-
nificantly changing metabolites were observed in the
vascular chamber compared to the brain chamber
(Fig. 8c, d). In addition to the global analysis of meta-
bolic trends in response to LPS, a number of signifi-
cantly changed metabolite compounds were identified
through database correlation (see the “Metabolite data
processing and analysis” section above, and the tenta-
tive structural identifications listed in Additional file
3). These preliminary identifications allow us to
prioritize that fatty acid and protein degradation path-
ways may be affected by LPS stimulation. When exam-
ining cytokine cocktail treatment after 24 h of
exposure, we see that the overlap between the vascular
and brain sides is increased with treatment (Fig. 8e, f ),
Fig. 7 Comparison of metabolites significantly affected by LPS and cytokine cocktail over time in both the vascular and brain chambers. a Venn
diagram of metabolites/compounds observed for the brain side of the NVU system in response to stimulation with LPS over time (6 and 24 h). b Venn
diagram of metabolites/compounds observed for the vascular side of the NVU system in response to stimulation with LPS over time (6 and 24 h). c
Graphical representation of the increase in the total number of features for the brain side. d Graphical representation of the increase in the total
number of features for the vascular side (significant criteria: p≤ 0.05 and fold change ≥│2│). e Venn diagram of metabolites/compounds observed
for the brain side of the NVU system in response to stimulation with cytokine cocktail (24 h). f Venn diagram of metabolites/compounds observed for
the vascular side of the NVU system in response to stimulation with cytokine cocktail (24 h). g Graphical representation of the increase in the total
number of features for the brain side. h Graphical representation of the increase in the total number of features for the vascular side (significant
criteria: p≤ 0.05 and fold change ≥│2│)
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and treatment with cytokine cocktail nearly doubles
the number of metabolites changed in both chambers
(Fig. 8g, h). Collectively, these two data sets reflecting
inflammatory drive show similar but not identical
metabolic signatures with regard to the BBB response.
Pathway identifications of metabolic response to
inflammatory stimulation
Using biologically driven computational analysis (mummi-
chog), metabolites observed in these studies were used to
predict metabolic network activity. In determining the BBB
response to cytokine cocktail response, network activity
analysis (or mummichog) was used to observe metabolites
affected either by consumption or production in response
to inflammatory stimulation (Fig. 9). These activity network
analyses allow our data to be grouped in pathways in an ef-
fort to identify network relationships between global
metabolic profiles (in this case, treated vs. untreated). In the
predictive activity network analysis for the vascular side of
the BBB, glutathione, CoA, and tryptophan are highlighted
as central nodes (Fig. 9a). On the brain side, CoA and tryp-
tophan are shared central nodes, as are dopamine and glu-
tamate (Fig. 9b). In addition to identifying central nodes of
metabolic interconnection, these analyses can also prioritize
the significance of specific metabolites in a known pathway
and identify specific pathways that are affected by our stud-
ies. For these analyses, we used both LPS and cytokine
cocktail data sets, and we observed multiple pathways that
were continuously highlighted regardless of barrier side or
inflammatory stimulation (see Fig. 10, red rows). Glycine,
serine, alanine, and threonine metabolism and aspartate
and asparagine metabolism indicate that protein synthesis
utilizes critical pathways that are changed upon inflamma-
tory stimulation.
Fig. 8 Comparison of the number of metabolites significantly affected by either LPS or cytokine cocktail over time and in both the vascular and
brain chambers. a Statistically significant metabolites/compounds observed for the brain side and the vascular side of the NVU system in
response to stimulation with 100 μg/mL LPS after 6 h of exposure. b Statistically significant metabolites/compounds observed for the brain side
and the vascular side of the NVU system in response to stimulation with 100 μg/mL LPS after 24 h of exposure. c Graphical representation of the
increase in the total number of features for the brain side and the vascular side at the 6-h time point. d Graphical representation of the increase
in the total number of metabolites/compounds for the brain side and the vascular side at the 24-h time point (significant criteria: p≤ 0.05 and
fold change ≥│2│). e Statistically significant metabolites/compounds observed for the brain side and the vascular side of the NVU system under
control conditions. f Statistically significant metabolites/compounds observed for the brain side and the vascular side of the NVU system in re-
sponse to stimulation with 100 ng/mL cytokine cocktail after 24 h of exposure. g Graphical representation of the increase in the total number of
features for the brain side and the vascular side under control conditions. h Graphical representation of the increase in the total number of me-
tabolites/compounds for the brain side and the vascular side at the 24-h time point (significant criteria: p≤ 0.05 and fold change ≥│2│)
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Fig. 9 Network module output from mummichog analysis of the qualitative and relative quantitative differences in metabolomic profiles of the
response to 100 ng/mL cocktail of IL-1, TNF-α, and MCP-1,2 stimulation for 24 h. Feature m/z values and significance measurements were used to
predict metabolic activity networks without the use of conventional MS/MS identification workflows. Metabolites are colored blue for negative
fold change or red for positive fold change, with the color intensity representing the magnitude of fold change and the size representing the stat-
istical significance (−log10(p value)). a Vascular chamber. b Brain chamber
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We also observed activated pathways specific to each side
of the BBB (see Fig. 10, yellow rows). For example, pyrimi-
dine metabolism is a pathway known for being involved
with systemic inflammation such as gout and arthritis, as
well as some neurodevelopmental disorders [55, 56], and
our data suggest its activation in the vascular chamber.
These data suggest a novel role for pyrimidine metabolism
in BBB response to inflammatory stimulation. In the case
of the brain side, the most prominent pathway implicated
in our network pathway analysis was drug metabolism in-
volving a canonical cytochrome P450 pathway for mediat-
ing the processing of antidepressants, antipsychotics, drugs
of abuse, endogenous neurochemicals such as serotonin
and dopamine, neurotoxins, and carcinogens [57] and neu-
roinflammation. There were also several pathways that
were treatment-specific (Fig. 10, purple rows). For example,
glutathione metabolism was observed for LPS but was not
present in the cytokine cocktail data, whereas for the cyto-
kine cocktail treatment, tryptophan metabolism was
strongly indicated. It is known that glutathione plays im-
portant roles in antioxidant defense, nutrient metabolism,
and regulation of cellular events, including cytokine pro-
duction and immune response, as well as gene expression,
DNA and protein synthesis, cell proliferation and apoptosis,
and signal transduction. In these data, we observe a broad
spectrum of metabolic activity consistent with what we
would expect for a compound such as LPS. We also ob-
served some interesting findings, such as the potential acti-
vation of tryptophan metabolism, which is critical as an
essential amino acid and a key player in serotonin produc-
tion, but is less known for its effect on inflammation [58].
Network activity analysis also allows us to prioritize the
further exploration of networks or metabolites of interest,
for example, the purine and pyrimidine pathways (Fig. 10).
If we compare activation in the brain side to the vascular
side of our BBB model, we observe numerous pathways
that are significantly changed in both sides but in opposite
directions (Figs. 10 and 11). The vascular chamber is mostly
up-regulating the pro-inflammatory pathway, while at the
same time, the brain chamber is mostly down-regulating
this pathway. By combining a novel micro-organ of a BBB
with cutting-edge metabolomics, we have been able to dras-
tically increase our understanding of the metabolic conse-
quences of inflammatory stimulation on the brain
microvasculature, as well as the neurons themselves.
Discussion
In the present study, we report that exposure of the
vascular chamber of the NVU to the inflammatory
stimulation of either LPS or a cytokine cocktail will in-
duce time-dependent changes in BBB function and
cytokine activation, as well as a global change of the
metabolomics profile on both the vascular and brain
chambers. Our data suggest that the initial response to
LPS stimulation is characterized by reduced tight junc-
tion formation and increased membrane permeability.
While it has been shown that LPS disrupts tight junc-
tions in numerous organ systems, including the gut and
Fig. 10 An analysis of the commonalities and differences in pathway activity between LPS and cocktail exposure
Brown et al. Journal of Neuroinflammation  (2016) 13:306 Page 14 of 17
lung [59, 60], very few studies have considered its ef-
fects on the BBB [61], and none have reported the
spontaneous recovery we found: after an increase in ex-
posure time (between 6 and 24 h), a recovery from the
initial exposure results in an increase in the formation
of tight junctions and a decrease in membrane perme-
ability from the 6-h time point, but not back to the
levels before exposure.
In addition to being able to analyze BBB changes in re-
sponse to LPS and cytokine cocktail, this unique microflui-
dic model has sufficient cell mass and low enough volume
to allow us to conduct cytokine analysis of the effluent from
both the vascular and brain sides at the time points chosen.
Previous studies have already demonstrated that cytokines
are often released in an oscillating fashion and may have
both pro- and anti-inflammatory properties, depending on
their release profiles [62–64]. The 3D cell culture made
possible by our NVU [23] enabled us to see and profile
cytokine activation based not only on when cytokines were
elevated but also on whether they were differentially ele-
vated in terms of vascular vs. brain compartment. Taken
collectively, these data argue for a cytokine activation model
whereby pro-inflammatory cytokines are activated in both
chambers at initial exposure, but at later time points, only a
subset remains activated in both compartments. The data
also suggest that at these later time points, pro-repair cyto-
kine activation is up-regulated in the brain compartment as
the BBB begins to rebound, whereas the vascular compart-
ment remains more pro-inflammatory.
Notable advances in identifying metabolites and un-
derstanding the significance of these measurements are
demonstrated in these studies. By leveraging IM-MS
with our organ-on-chip model of the BBB, we were able
to obtain a more thorough investigation of metabolite
changes due to neuroinflammation. In these studies, our
data suggest that (1) inflammation involving the BBB is
closely linked to protein synthesis, (2) different sides of
the barrier use different proteomic and metabolic path-
ways to respond to inflammatory signals, and (3) even
when the same pathway is involved, the vasculature
could be driving pro-inflammatory processes while the
brain is ramping down inflammation.
Conclusions
This work integrated several new technologies, including
microfluidic organs-on-chips as in vitro models, IM-MS
metabolomics, and pathway identification, and it is from
this integration that we have gained new insights into BBB
response to inflammatory stimulation. We have shown in-
flammatory disruption of the BBB and transport of the in-
flammatory signals across the BBB, mapped changes in
cytokine to barrier disruption, and created a detailed ana-
lysis of the metabolic signature and metabolic pathways
associated with inflammatory stimulation.
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